Free UK shipping over £100Same-day dispatch before 2PM Mon–FriHigh-purity research productsCall or WhatsApp 07840 001329
Product documentation
Certificate of analysis
View COA

LABORATORY RESEARCH MATERIAL

Tirzepatide

Price range: £34.99 through £119.99

Compound
Tirzepatide
Amount per vial
10mg
Royal Mail Tracked delivery
UK delivery only
Delivery details
  • Royal Mail Tracked 48 (2–3 working days)£3.95
  • Royal Mail Tracked 24 (next working day)£5.95
  • Free UK shipping on orders over £100
DispatchOrders placed before 2pm Monday–Friday are dispatched the same day.

For laboratory and research use only. Not for human consumption. You must be 18 or over to order.

Product documentation
Certificate of analysis
View COA

PRODUCT INFORMATION

Details & documentation

Description

Tirzepatide 10 mg, 20 mg, 30 mg and 40 mg

Buy Tirzepatide 10 mg, 20 mg, 30 mg or 40 mg for laboratory research. Each vial contains tirzepatide as lyophilized powder, in the labelled amount for the size selected.

  • 10 mg: per vial
  • 20 mg: per vial
  • 30 mg: per vial
  • 40 mg: per vial

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. A C20 fatty diacid is attached to a lysine side chain through a linker, which promotes albumin binding. It is identified by CAS 2023788-19-2.

Choose the size

The four vial sizes contain the same compound in different labelled amounts. Larger vials provide more material from a single lot; smaller vials suit pilot work.

Tirzepatide is a dual GIP/GLP-1 receptor agonist and should not be confused with single-receptor GLP-1 agonists such as semaglutide, or with triple agonists such as retatrutide, which are different molecules.

What the research establishes

Coskun and colleagues described the discovery of tirzepatide (then LY3298176). In cell lines expressing incretin receptors, it activated both GIP and GLP-1 receptor signalling. In mice, it produced glucose-dependent insulin secretion and improved glucose tolerance, with contributions from both receptors. The same paper reported early phase 1 studies.

Tirzepatide was subsequently evaluated in Eli Lilly’s SURPASS and SURMOUNT clinical trial programmes and is an approved medicine. Those findings concern the regulated medicinal product in defined clinical populations under trial conditions; they do not describe the performance of this research material, which is not a medicine.

Review the COA and product files

COA & Documentation contains the available batch reports and product documentation. Check the lot and strength, confirm identity by mass spectrometry against the expected molecular weight of the lipidated peptide, and note how purity was measured.

The strengths above describe labelled material, not a measured result for every lot. For handling and storage, consult the records that apply to your batch.

Additional information

Strength

10mg, 20mg, 30mg, 40mg

CAS No.

2023788-19-2

Product Format

Vial, Pre-loaded Cartridge, Pre-loaded Disposable Pen

Purity

≥99%

Applications

GIP and GLP-1 receptor research, incretin signalling studies, glucose metabolism investigations.

Synthesis

Solid-phase synthesis

Format

Lyophilized powder

Solubility

Soluble in water or 1% acetic acid

Stability & Storage

Stable for 24 months at -20°C in lyophilized form.

Appearance

White lyophilized powder

Shipping Conditions

Shipped at room temperature. Upon receipt, store at -20°C

Regulatory/Compliance

Complies with research use only standards. Not for drug, household, or other uses.

Batch documentation

Every batch, on record.

The certificate of analysis for the selected strength, with the results it reports and earlier batches. Certificates are published only after they have been received and reviewed.

20mg, VialCertificate on file
Purity (HPLC)
99.92%
Lot
TIRZ20-006
Test date
02 Apr 2026
Laboratory
Freedom Diagnostics
Measured content
27.65mg (avg per vial)
View certificate (PDF)
Reported results
TestMethodResult
Mass identificationHPLC-UV + MSTirzepatide (GLP TZ) confirmed
PurityHPLC-UV99.92% average of three vials
Net peptide contentAs reported27.65 mg average per vial
AppearanceAs reportedWhite lyophilized powder
Endotoxin (replicate 1)Threshold ≤0.05 EU/mLPass
Endotoxin (replicate 2)Threshold ≤0.05 EU/mLPass

Research-use notice

This product is supplied strictly for laboratory, analytical and research purposes. It is not intended for human or veterinary use, consumption, diagnosis, treatment or self-administration. Read our Research-Use Disclaimer.

YOU MAY ALSO LIKE

Related research products

Semaglutide

Price range: £34.99 through £74.99

Melanotan I

Price range: £22.99 through £62.99

Lipo-C

Price range: £24.99 through £64.99

Glutathione

Price range: £34.99 through £74.99

Pepto Pure Labs

PLEASE CONFIRM

Research Use Only

By entering this website, you confirm that you are 18 years of age or older and understand that products supplied by Pepto Pure Labs are intended strictly for laboratory, analytical and research purposes only.

Products are not intended for human consumption, diagnosis, treatment or self-administration.